Study Stopped
Myriad has discontinued the development of Flurizan.
Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol
Open Label Study of the Effect of Daily Treatment With MPC-7869 in Subjects With Dementia of the Alzheimer's Type
1 other identifier
interventional
1,000
2 countries
90
Brief Summary
Open-label treatment with MPC-7869 for participants in a previous randomized study.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Sep 2006
90 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2006
CompletedFirst Submitted
Initial submission to the registry
September 21, 2006
CompletedFirst Posted
Study publicly available on registry
September 25, 2006
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2008
CompletedAugust 5, 2008
August 1, 2008
September 21, 2006
August 1, 2008
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Primary Safety
For study duration
Study Arms (1)
Open Label Arm
OTHERTreatment is open-label
Interventions
Eligibility Criteria
You may qualify if:
- Participation in a previous MPC-7869 randomized protocol
- Have had a diagnosis of probable Alzheimer's disease.
- Men or women ages 55 years or greater and living in the community at the time of enrollment (i.e., not living in a rest home or nursing care facility).
- Signed the subject Informed Consent Form and is willing and able to participate for the duration of the study.
- Female subjects must be surgically sterile or postmenopausal for \> 1 year.
- Subjects must have a reliable caregiver who can read, understand and speak English or Spanish.
You may not qualify if:
- History or evidence of, active malignancy, except for basal cell carcinoma or squamous cell carcinoma of the skin, within the 24 months prior to entry. Men with prostate cancer may be enrolled at the discretion of the sponsor.
- Chronic or acute renal, hepatic or metabolic disorder.
- Use of any investigational therapy within 30 days, or 5 half-lives, whichever is longer, and/or use of AD immunotherapy prior to screening.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Myrexis Inc.lead
Study Sites (90)
Unknown Facility
Alabaster, Alabama, United States
Unknown Facility
Huntsville, Alabama, United States
Unknown Facility
Phoenix, Arizona, United States
Unknown Facility
Sun City, Arizona, United States
Unknown Facility
Tucson, Arizona, United States
Unknown Facility
Costa Mesa, California, United States
Unknown Facility
Irvine, California, United States
Unknown Facility
Lafayette, California, United States
Unknown Facility
Laguna Hills, California, United States
Unknown Facility
Long Beach, California, United States
Unknown Facility
Rancho Mirage, California, United States
Unknown Facility
Sacramento, California, United States
Unknown Facility
San Diego, California, United States
Unknown Facility
San Francisco, California, United States
Unknown Facility
Vista, California, United States
Unknown Facility
Danbury, Connecticut, United States
Unknown Facility
Darien, Connecticut, United States
Unknown Facility
New Haven, Connecticut, United States
Unknown Facility
Washington D.C., District of Columbia, United States
Unknown Facility
Deerfield Beach, Florida, United States
Unknown Facility
Fort Meyers, Florida, United States
Unknown Facility
Fort Myers, Florida, United States
Unknown Facility
Hollywood, Florida, United States
Unknown Facility
Jacksonville, Florida, United States
Unknown Facility
Miami, Florida, United States
Unknown Facility
Naples, Florida, United States
Unknown Facility
Sunrise, Florida, United States
Unknown Facility
Tampa, Florida, United States
Unknown Facility
West Palm Beach, Florida, United States
Unknown Facility
Atlanta, Georgia, United States
Unknown Facility
Chicago, Illinois, United States
Unknown Facility
Fort Wayne, Indiana, United States
Unknown Facility
Indianapolis, Indiana, United States
Unknown Facility
Lexington, Kentucky, United States
Unknown Facility
Baltimore, Maryland, United States
Unknown Facility
Glen Burnie, Maryland, United States
Unknown Facility
Boston, Massachusetts, United States
Unknown Facility
West Yarmouth, Massachusetts, United States
Unknown Facility
Ann Arbor, Michigan, United States
Unknown Facility
Grand Rapids, Michigan, United States
Unknown Facility
Rochester, Minnesota, United States
Unknown Facility
St Louis, Missouri, United States
Unknown Facility
Lebanon, New Hampshire, United States
Unknown Facility
Kenilworth, New Jersey, United States
Unknown Facility
Morristown, New Jersey, United States
Unknown Facility
Princeton, New Jersey, United States
Unknown Facility
Stratford, New Jersey, United States
Unknown Facility
Albuquerque, New Mexico, United States
Unknown Facility
Albany, New York, United States
Unknown Facility
Brooklyn, New York, United States
Unknown Facility
Elmsford, New York, United States
Unknown Facility
New York, New York, United States
Unknown Facility
Olean, New York, United States
Unknown Facility
Rochester, New York, United States
Unknown Facility
Syracuse, New York, United States
Unknown Facility
Durham, North Carolina, United States
Unknown Facility
Raleigh, North Carolina, United States
Unknown Facility
Centerville, Ohio, United States
Unknown Facility
Columbus, Ohio, United States
Unknown Facility
Toledo, Ohio, United States
Unknown Facility
Oklahoma City, Oklahoma, United States
Unknown Facility
Eugene, Oregon, United States
Unknown Facility
Portland, Oregon, United States
Unknown Facility
Jenkintown, Pennsylvania, United States
Unknown Facility
Philadelphia, Pennsylvania, United States
Unknown Facility
Pittsburgh, Pennsylvania, United States
Unknown Facility
Scotland, Pennsylvania, United States
Unknown Facility
East Providence, Rhode Island, United States
Unknown Facility
Beaufort, South Carolina, United States
Unknown Facility
Charleston, South Carolina, United States
Unknown Facility
Greer, South Carolina, United States
Unknown Facility
Memphis, Tennessee, United States
Unknown Facility
Nashville, Tennessee, United States
Unknown Facility
Dallas, Texas, United States
Unknown Facility
Houston, Texas, United States
Unknown Facility
San Antonio, Texas, United States
Unknown Facility
Ogden, Utah, United States
Unknown Facility
Salt Lake City, Utah, United States
Unknown Facility
Bennington, Vermont, United States
Unknown Facility
Alexandria, Virginia, United States
Unknown Facility
Charlottesville, Virginia, United States
Unknown Facility
Virginia Beach, Virginia, United States
Unknown Facility
Middleton, Wisconsin, United States
Unknown Facility
Milwaukee, Wisconsin, United States
Unknown Facility
Winnepeg, Manitoba, Canada
Unknown Facility
Halifax, Nova Scotia, Canada
Unknown Facility
Kingston, Ontario, Canada
Unknown Facility
Ottawa, Ontario, Canada
Unknown Facility
Toronto, Ontario, Canada
Unknown Facility
Regina, Saskatchewan, Canada
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Mark Laughlin, MD
Myrexis Inc.
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
September 21, 2006
First Posted
September 25, 2006
Study Start
September 1, 2006
Study Completion
December 1, 2008
Last Updated
August 5, 2008
Record last verified: 2008-08